700 - The Pros, Cons, and Unknowns of Ozempic episode artwork

EPISODE · Dec 15, 2023 · 19 MIN

700 - The Pros, Cons, and Unknowns of Ozempic

from Public Health On Call · host Johns Hopkins Bloomberg School of Public Health

Medications like Ozempic, Wegovy, and Mounjaro show lots of promise for treating obesity but scientists still don't understand exactly how they work. There's also a lack of data to show whether these medications are safe to take long term. Dr. Sameer Khan, a Johns Hopkins fellow in gasteroenterology, talks with Dr. Josh Sharfstein about what these medicines are and what they can do, the questions that remain, and why it's a challenge for clinicians to prescribe them and for patients to actually obtain them. Learn more about another one of our projects, the Expert Insights newsletter: publichealth.jhu.edu/subscribe

Episode metadata supplied by the publisher feed · Published Dec 15, 2023

Embed this episode

NOW PLAYING

700 - The Pros, Cons, and Unknowns of Ozempic

0:00 19:02

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Public Health On Call?

This episode is 19 minutes long.

When was this Public Health On Call episode published?

This episode was published on December 15, 2023.

Can I download this Public Health On Call episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!